Johnson, P. Connor
Abramson, Jeremy S.
Article History
Accepted: 10 September 2021
First Online: 20 January 2022
Declarations
:
: P. Connor Johnson declares that he has no conflict of interest. JSA reports consulting for Allogene, Celgene, Juno Therapeutics, Kite Pharma, and Novartis. Jeremy S. Abramson has received compensation from AstraZeneca and Genmab for service as a consultant; has received speaker’s honoraria from Celgene and Regeneron; and has received compensation for participation on scientific advisory boards from Celgene, Juno Therapeutics, AbbVie, EMD Serono, Genentech/Roche, Janssen, Karyopharm Therapeutics, Gilead Sciences, Verastem Oncology, Bayer, Merck, Kite Pharma, Amgen, Mustang Bio, Century Therapeutics, Epizyme Seattle Genetics, Allogene Therapeutics, MorphoSys, C4 Therapeutics, Incyte Corporation, and BeiGene.